US: AKBLF - ALK-Abelló A/S

Доходность за полгода: +46.12%

График акции ALK-Abelló A/S


О компании

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

Подробнее
It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Валюта usd
Сайт https://www.alk.net
Sector Health Care
Industry Biotechnology
Валюта отчета dkk
Цена ао 27.03
Изменение цены за день: 0% (27.0328)
Изменение цены за неделю: +9.89% (24.6)
Изменение цены за месяц: +24.69% (21.68)
Изменение цены за 3 месяца: +33.17% (20.3)
Изменение цены за полгода: +46.12% (18.5)
Изменение цены за год: +137.13% (11.4)
Изменение цены за 3 года: -94.45% (487)
Изменение цены за 5 лет: -87.8% (221.5)
Изменение цены с начала года: +104.02% (13.25)

Недооценка

Название Значение Оценка
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Итого: 2.5

Эффективность

Название Значение Оценка
ROA, % 0 0
ROE, % 0 0
Итого: 0

Дивиденды

Название Значение Оценка
Div yield, % 0 0
DSI 1 10
Итого: 1.6056

Долг

Название Значение Оценка
Debt/EBITDA 0 10
Итого: 10

Импульс роста

Название Значение Оценка
Доходность Revenue, % 47.34 6
Доходность Ebitda, % 268.55 10
Доходность EPS, % -833.33 0
Итого: 3.2

Руководитель Должность Оплата Год рождения
Mr. Claus Steensen Solje Executive VP, CFO & Member of Management Board 1972 (52 года)
Mr. Søren Daniel Niegel Executive VP of Commercial Operations & Member of Management Board 1971 (53 года)
Dr. Henriette Mersebach Executive VP Research & Development & Member of Management Board 1971 (53 года)
Ms. Katja Barnkob Thalund Project Director of Global CMC Development & Employee-elected Director 1969 (55 лет)
Ms. Lise Lund Maerkedahl Project Director of Global Research & Employee-elected Director 1967 (57 лет)
Mr. Peter Halling President & CEO 1977 (47 лет)
Mr. Per Plotnikof VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Prof. Hendrik Kees Kam Nolte M.D., Ph.D. Senior Vice President of Research & Development - North America and International Markets
Mr. Christian G. Houghton Head of Product Supply
Mr. Peter Sejer Andersen Senior Vice President of Global Research & Drug Discovery

Адрес: Denmark, Horsholm, BOege AllE 6-8 - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.alk.net